Recursion to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Recursion (NASDAQ: RXRX), a biotechnology firm focused on drug discovery, announced its participation in two major investor conferences:

• KeyBanc Capital Markets Emerging Technology Summit — March 8-9, 2022
• SVB Leerink Mountain Meeting — March 20-23, 2022

Webcasts will be accessible via the investor section on their website. Recursion utilizes advanced technologies to enhance drug discovery, boasting one of the largest biological datasets and powerful computational resources, aiming to revolutionize medicine.

SALT LAKE CITY, March 2, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:

• KeyBanc Capital Markets Emerging Technology Summit — March 8 through March 9, 2022
• SVB Leerink Mountain Meeting — March 20 through March 23, 2022

Webcasts may be found in the investor section of the Recursion website at www.Recursion.com. 

About Recursion
Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Enabling its mission is the Recursion Operating System, a platform built across diverse technologies that continuously expands one of the world's largest proprietary biological and chemical datasets, the Recursion Data Universe. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset the Recursion Map, a collection of hundreds of billions of searchable inferences across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. 

The company is proudly headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn. 

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursion's mission; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; expansion of facilities and expected uses; workforce growth; employee stock trading plans; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as "plan," "will," "expect," "anticipate," "intend," "believe," "potential," "continue," and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; the impact of the COVID-19 pandemic and force majeure events; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; and other risks and uncertainties such as those described under the heading "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q. All forward-looking statements are based on management's current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/recursion-to-participate-in-upcoming-investor-conferences-301494043.html

SOURCE Recursion

FAQ

What are the dates for Recursion's investor conferences in March 2022?

Recursion will participate in the KeyBanc Capital Markets Emerging Technology Summit from March 8-9, 2022, and the SVB Leerink Mountain Meeting from March 20-23, 2022.

Where can I find the webcasts for Recursion's investor conferences?

Webcasts for Recursion's investor conferences can be found in the investor section of their website.

What is the main focus of Recursion as a biotechnology company?

Recursion is focused on industrializing drug discovery by decoding biology, utilizing advanced technologies and machine-learning algorithms.

What is the significance of the Recursion Data Universe?

The Recursion Data Universe is one of the world's largest proprietary biological and chemical datasets, essential for their drug discovery efforts.

How does Recursion utilize computational resources in drug discovery?

Recursion operates one of the most powerful supercomputers, enabling massive experimental and computational scale to advance drug discovery.